Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR)

Maxim Group started coverage on shares of Citius Oncology (NASDAQ:CTOR) in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $3.00 price objective on the stock.

Citius Oncology Stock Down 2.2 %

Shares of CTOR opened at $0.92 on Wednesday. Citius Oncology has a one year low of $0.85 and a one year high of $49.00. The company has a 50-day moving average price of $1.16.

Citius Oncology Company Profile

TenX Keane Acquisition Corp. is a blank check company. It formed for the purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. TenX Keane Acquisition Corp. is based in New York.